Page last updated: 2024-12-05

cdta

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

CDTA: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10213
CHEBI ID188859
SCHEMBL ID367170
MeSH IDM0046897

Synonyms (69)

Synonym
CBDIVE_014740
nsc529593
o-cyclohexanediaminetetraacetic acid
482-54-2
1,n'-tetraacetic acid
acetic acid,2-cyclohexylenedinitrilo)tetra-
1,2-cyclohexylenedinitrilotetraacetic acid
(1,2-cyclohexylenedinitrilo)tetraacetic acid
1,2-cyclohexanediaminetetraacetic acid
1,2-diaminocyclohexanetetraacetic acid
glycine,n'-1,2-cyclohexanediylbis[n-(carboxymethyl)-
cdta
chel 600
nsc7339
1,2-cyclohexylenediaminetetraacetic acid
wln: l6tj an1vq1vq bn1vq1vq
1,n,n',n'-tetraacetic acid
octa
cydta
cgta
cyclohex-1,2-ylenediaminetetra(acetic acid)
1,2-diaminocyclohexane-n,n'-tetraacetic acid
glycine, n,n(sup 1)-1,2-cyclohexanediylbis(n-(carboxymethyl)-
acetic acid, (1,2-cyclohexylenedinitrilo)tetra-
kyselina 1,2-cyklohexylendiamintetraoctova [czech]
komplexon iv
glycine, n,n'-1,2-cyclohexanediylbis(n-(carboxymethyl)-
einecs 207-582-7
1,2-diaminocyclohexane-n,n,n',n'-tetraacetic acid
1,2-cyclohexanediamine-n,n,n',n'-tetraacetic acid
nsc 529593
cyclohexanediamine tetraacetic acid
UNM000000709501
FT-0650567
AKOS001695975
cyclohexane-1,2-diaminetetraacetic acid
CHEBI:188859
2-[[2-[bis(carboxymethyl)amino]cyclohexyl]-(carboxymethyl)amino]acetic acid
A806528
glycine, n,n'-1,2-cyclohexanediylbis[n-(carboxymethyl)-
A827506
2,2',2'',2'''-(cyclohexane-1,2-diylbis(azanetriyl))tetraacetic acid
kyselina 1,2-cyklohexylendiamintetraoctova
2-({2-[bis(carboxymethyl)amino]cyclohexyl}(carboxymethyl)amino)acetic acid
FT-0606334
1,2-diaminocyclohexanetetraacetic acid monohydrate
AB01333215-02
SCHEMBL367170
123333-90-4
glycine,n,n'-trans-1,2-cyclohexanediylbis[n-(carboxymethyl)-, hydrate (9ci)
glycine,n,n'-trans-1,2-cyclohexanediylbis[n-(carboxymethyl)-,hydrate(9ci)
mfcd00066429
SR-01000086307-1
sr-01000086307
FCKYPQBAHLOOJQ-UHFFFAOYSA-N
DTXSID80862002
1,2-cyclohexylenedinitrilotetraaceticacid
18763-65-0
DS-12593
O10552
2,2',2'',2'''-(cyclohexane-1,2-diy-lbis(azanetriyl))tetraacetic acid
NCGC00342298-01
AKOS016842375
2((carboxymethyl){2[(carboxymethyl)(2hydroxy2oxoethyl)amino]cyclohexyl}amino)acetic acid
1,2-diaminocyclohexanetetraacetic acid tetrasodium salt solution
CS-0155356
SY112606
2,2 inverted exclamation mark ,2 inverted exclamation mark inverted exclamation mark ,2 inverted exclamation mark inverted exclamation mark inverted exclamation mark -[cyclohexane-1,2-diylbis(azanetriyl)]tetraacetic acid
PD157953

Research Excerpts

Treatment

CDTA-treatment of rabbit skeletal natural actomyosin resulted in the complete removal of troponin C and the abolishment of Ca2+-activated ATPase activity. Treatment with CDTA at 1080 mg/kg/day resulted in a high level of maternal deaths, as well as less severe clinical signs.

ExcerptReferenceRelevance
"CDTA-treatment of rabbit skeletal natural actomyosin resulted in the complete removal of troponin C and the abolishment of Ca2+-activated ATPase activity. "( Removal of troponin C from natural actomyosin of rabbit skeletal muscle by CDTA.
Ohtsuki, I; Shiraishi, F, 1989
)
1.95
"The CDTA-treated myofibrils, when reconstituted with skeletal troponin C, showed almost exactly the same Ca2+- or Sr2+-sensitive ATPase activity as that of intact myofibrils."( Ca2+- and Sr2+-sensitivity of the ATPase activity of rabbit skeletal myofibrils: effect of the complete substitution of troponin C with cardiac troponin C, calmodulin, and parvalbumins.
Morimoto, S; Ohtsuki, I, 1987
)
0.75
"The CDTA-treated fibers lost all of the troponin C and showed no Ca2+-activated tension development."( Restoration of Ca2+-activated tension of CDTA-treated single skeletal muscle fibers by troponin C.
Fujiwara, T; Morimoto, S; Ohtsuki, I, 1988
)
1.02
"Treatment with CDTA at 1080 mg/kg/day resulted in a high level of maternal deaths, as well as less severe clinical signs (significant reduction in weight gain and food consumption)."( Developmental toxicity of cyclohexanediaminetetraacetic acid (CDTA) in mice.
Colomina, MT; Corbella, J; Domingo, JL; Llobet, JM; Sánchez, DJ, 1994
)
0.87

Toxicity

The no observable adverse effect level (NOAEL) for maternal and developmental toxicity of CDTA in mice was 540 mg/kg/day. The LD50 of the following metal-binding chelating drugs, EDTA, diethylenetriaminepentaacetic acid (DTPA), hydroxyethylenediaminetriaceticacid (HEDTA) and triethylenetetraminehexaacetic Acid (TTHA) was evaluated in terms of mortality in rats after intraperitoneal administration.

ExcerptReferenceRelevance
"The LD50 of the following metal-binding chelating drugs, EDTA, diethylenetriaminepentaacetic acid (DTPA), hydroxyethylenediaminetriacetic acid (HEDTA), cyclohexanediaminotetraacetic acid (CDTA) and triethylenetetraminehexaacetic acid (TTHA) was evaluated in terms of mortality in rats after intraperitoneal administration and was found to be in the order: CDTA greater than EDTA greater than DTPA greater than TTHA greater than HEDTA."( Evaluation of LD50 of some polyaminocarboxylic acids used as chelating drugs in metal intoxication.
Athar, M; Behari, JR; Dwivedi, PP; Srivastava, RC,
)
0.32
" The no observable adverse effect level (NOAEL) for maternal and developmental toxicity of CDTA in mice was 540 mg/kg/day."( Developmental toxicity of cyclohexanediaminetetraacetic acid (CDTA) in mice.
Colomina, MT; Corbella, J; Domingo, JL; Llobet, JM; Sánchez, DJ, 1994
)
0.75

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic results were complementary with those of the biodistribution studies and provide a basis for the study of in vivo metabolic mechanisms of linker-immunoconjugates."( Introduction of five potentially metabolizable linking groups between 111In-cyclohexyl EDTA derivatives and F(ab')2 fragments of anti-carcinoembryonic antigen antibody--II. Comparative pharmacokinetics and biodistribution in human colorectal carcinoma-bea
Chatal, JF; Faivre-Chauvet, A; Gestin, JF; Mease, RC; Meinken, GE; Sai-Maurel, C; Slinkin, M; Srivastava, SC; Thédrez, P, 1993
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organooxygen compoundAn organochalcogen compound containing at least one carbon-oxygen bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
UDP-u03B1-D-glucose biosynthesis I1424
dolichyl glucosyl phosphate biosynthesis412
UDP-glucose biosynthesis39

Research

Studies (113)

TimeframeStudies, This Drug (%)All Drugs %
pre-199042 (37.17)18.7374
1990's25 (22.12)18.2507
2000's14 (12.39)29.6817
2010's15 (13.27)24.3611
2020's17 (15.04)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 77.82

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index77.82 (24.57)
Research Supply Index4.80 (2.92)
Research Growth Index4.74 (4.65)
Search Engine Demand Index134.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (77.82)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (0.83%)6.00%
Case Studies1 (0.83%)4.05%
Observational1 (0.83%)0.25%
Other117 (97.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]